Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib (BI 6727), a selective Polo‐like kinase inhibitor. The primary endpoints were the maximum tolerated dose of volasertib and the incidence of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Yukio, Yamauchi, Takahiro, Kiyoi, Hitoshi, Sakura, Toru, Hata, Tomoko, Ando, Kiyoshi, Watabe, Aiko, Harada, Akiko, Taube, Tillmann, Miyazaki, Yasushi, Naoe, Tomoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714695/
https://www.ncbi.nlm.nih.gov/pubmed/26471242
http://dx.doi.org/10.1111/cas.12814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714695/
https://www.ncbi.nlm.nih.gov/pubmed/26471242
http://dx.doi.org/10.1111/cas.12814

Ejemplares similares